Turning great ideas into healthier communities


Prioritizing Multipurpose Prevention Technology Development and Investments Using a Target Product Profile

2013 | Antiviral Research

Multipurpose prevention technologies (MPTs) represent a powerful opportunity to address the unmet sexual and reproductive health needs of women in at-risk populations around the world in an efficient and cost-effective manner. The development of MPT products for the combination prevention of pregnancy and sexually transmitted infections (including HIV) is a high-risk/high-gain, expensive process. The associated challenges are compounded by limitations in available resources for the development, evaluation, and delivery of such products.

Consequently, an objective process for identifying MPT products with the highest public health impact potential is necessary to serve as the basis of coordinated investment of supporting agencies in the development of such products. Moreover, this process would serve as a framework for product development organizations, guiding their product development strategies.

The Scientific Agenda Working Group of the Initiative for Multipurpose Prevention Technologies conducted an MPT pipeline evaluation exercise for the purpose of defining specific MPT product priorities, and to identify MPT technology gaps which need to be addressed in order to achieve development of optimal products.

Read the article.

Through a formal and objective process, a set of MPT priority product recommendations emerged, along with several priority MPT gaps. Further, specific MPT development process priorities were identified. The detailed process and summary findings of this exercise are presented here. This article is based on a presentation at the “Product Development Workshop 2013: HIV and Multipurpose Prevention Technologies,” held in Arlington, Virginia on February 21–22, 2013. It forms part of a special supplement to Antiviral Research.

article Highlights

  • Priority multipurpose prevention technology products focus on HIV, STI, and unintended pregnancy.
  • High-impact MPT must be optimized regarding drug and formulation type.
  • Drugs with established safety and efficacy and acceptable dosage forms are crucial.
  • Coordinated investment and collaborative MPT development are critical to success.


Romano, J., Manning, J., Hemmerling, A., McGrory, E., & Young Holt, B.
PHI PI/PD:, Bethany Young Holt

Produced through PHI's:

CAMI Health